The series focuses on outcomes research in chronic kidney disease and end-stage renal disease, delivery of care in dialysis units and chronic kidney disease clinics, emerging data on new treatments compared to current standard of care, continuing review of kidney biopsy pathology, and basic science research that may become future therapeutics.
Key Words: Nephrology, Renal Disease, Kidneys, Acute kidney injuries, Hypertension
- Physician
- Nurse Practitioner
- Physician Assistant
- Nurse
- Medical Students, Trainees
Participants who engage in this educational intervention will be able to:
- Recognize the epidemiology and outcomes of HRS-1 in the US
- Identify pathophysiologic mechanisms that lead to HRS-1 and impact susceptibility to treatment related adverse events
- Compare and contrast the effectiveness of various vasoconstrictor therapies in HRS-1
Speaker:
Kevin Regner, MD
Chief | Professor
Division of Nephrology
Medical College of Wisconsin
Activity Directors:
Dawn Wolfgram, MD
Associate Professor
Department of Medicine
Division of Nephrology
Medical College of Wisconsin
Planning Committee Member(s):
In accordance with the ACCME® Standards for Integrity and Independence in Accredited Continuing Education, Standard 3, all in control of content must disclose any relevant financial relationships. The following in control of content had no relevant financial relationships to disclose.
- Dawn Wolfgram
The following persons in control of content disclosed the following financial relationships which were reviewed via the MCW conflict of interest mitigation process and addressed.
Name | Company | Role |
---|---|---|
Kevin Regner, MD | Mallinkrodt Pharma | Advisory Committee |
Contact
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.